Deciphera to present data from DCC-3014 trial at CTOS annual meet

	The ongoing clinical trial of DCC-3014 have shown preliminary anti-tumor activity. 
	 
	DCC-3014 validates emerging tolerability profile with no Grade 3 or Higher TEAEs.
	 
	Encore presentation of data from the INVICTUS Pivotal Phase 3 Study clinical trial will be presented in an oral presentation session.


Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has reportedly announced the preliminary data from its Phase 1 clinical trial of DCC-3014, an oral inhibitor of CSF1R in patients who are suffering from diffuse-type TGCT (tenosynovial giant cell tumor), as well as encore representation of INVICTUS pivotal Phase 3 clinal trial of ripretinib, a broad-spectrum KIT/ PDGFRα inhibitor in patients who are suffering from advanced GIST (gastrointestinal stromal tumors).

Reportedly, results from these clinical trials will be presented at CTOS (Connective Tissue Oncology Society) annual meeting which will be held in Tokyo, Japan.  

According to Matthew L. Sherman, M.D., Chief Medical Officer and Executive Vice President of Deciphera, the company is thrilled to give out preliminary data from the initial TGCT patients who are registered in the ongoing Phase 1 study of DCC-3014. Even though, the TGCT program is in initial stages, Deciphera is encouraged by the evidence of anti-tumor activity along with emerging tolerability profile, he said.

Moreover, the company will register more TGCT patients to determine the potential of DCC-3014 to make an effective impact on the progression of disease and quality of life of patients, Sherman added.

Reportedly, Deciphera’s Phase 1 clinical trial of DCC-3014 was designed to determine the pharmacokinetics, pharmacodynamics, and safety of multiple doses of DCC-3014 in patients who are suffering from TGCT and solid tumors. 

Meanwhile, based on the positive INVICTUS data, the company expects to submit a new drug application to U.S. FDA for ripretinib for the treatment of patients who are suffering from advanced GIST in Q1 2020.

Source Credit - https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-inc-present-data-dcc-3014-and